ARTS-HF is a IIb phase clinical trial that demonstrated that Finerenone was well tolerated and determined a significant reduction in NT proBNP levels in patients with WHF and diabetes mellitus and/or chronic kidney disease [62]. Here, NPPB is linked to chronic kidney disease.